News

NMS Group S.p.A. has announced the appointment of Andrew Curtis as Chief Strategy Officer reporting to the Group CEO, effective immediately. Andrew brings to NMS Group three decades of experience as a global corporate strategy and business leader from biotech and pharma sectors. He is based in the US, working from the US subsidiary (Nerviano Medical Sciences Inc.) in Boston just opened this month.
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. (NMS Srl), announced today that it has expanded its presence in the US with the creation of a new US subsidiary, Nerviano Medical Sciences Inc. Nerviano Medical Sciences Inc. is incorporated in Delaware State while the company’s activities will be mostly concentrated in the Boston, Massachusetts area. The US subsidiary is part of NMS Srl and its holding NMS Group’s aggressive transformation plan to fortify further the Group’s footprint and accelerate its pace in expanding in the world’s key biotech and pharmaceutical market.
(Click the title for the complete article)

NMS-812 is a novel potent oral inhibitor of PERK (PKR-like endoplasmic reticulum kinase) that also inhibits GCN2 (General Control Nonderepressible 2). PERK and GCN2 are effectors of the Integrated Stress Response (ISR), a pro-survival pathway exploited by cancer cells to survive stress. PERK is a key effector of the unfolded protein response (UPR) and GCN2 is a sensor of amino acid deficiency. Both proteins modulate the eIF2α/ATF4 axis promoting tumor survival and drug resistance as well as, via direct and indirect mechanisms, the immune response.
(Click the title for the complete article)

Nerviano, 29 June 2022
The Board of Directors of NMS Group S.p.A has approved today the company’s annual financial report, including the consolidated financial statements of the Group as of 31 December 2021.
(Click the title for the complete article)

Nerviano, 28 June 2022
Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is pleased to announce the signing of the agreement with Università del Piemonte Orientale, faculty of Pharmaceutical Sciences in Novara (DSF), as part of the National Operational Programme on Research and Innovation 2014-2020 (Programma Operativo Nazionale (PON) – “RICERCA E INNOVAZIONE” 2014-2020). The Programme is the key instrument with which the Italian government contributes to the improvement of the quality of higher education and the enhancement of research, technological development and innovation.
(Click the title for the complete article)

Nerviano, 31 May 2022
BrYet Health Inc starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer. BrYet is an American biotechnology company based in Houston TX founded for the purpose of developing and bringing to market drugs for prevention and treatment of multiple types of metastatic cancer, based on a disruptive approach developed by Prof. Mauro Ferrari: Transport Oncophysics. BrYet will collaborate with our strategic production partner NerPharMa, a leading CDMO in oncology, to scale-up the drug substance manufacturing process and the finished product to supply material for clinical programs with potential upside to future world-wide commercial sales. The company’s goal is to start ML-016 clinical trials in the second half of 2023.
(Click the title for the complete article)